Anti-Human CD37 Recombinant Antibody (Otlertuzumab) (CAT#: TAB-904)

Recombinant humanized (from mouse) antibody expressed in CHO binding to human CD37. Otlertuzumab is a humanized monoclonal antibody designed for the treatment of cancer


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Gene Expression
  • Datasheet
  • MSDS
  • COA

Figure 1 Serum concentrations of otlertuzumab were measured at multiple time points throughout the dosing cycle and mean concentrations over time are plotted for all 3 NHL treatment groups.

Figure 1 Serum concentrations of otlertuzumab were measured at multiple time points throughout the dosing cycle and mean concentrations over time are plotted for all 3 NHL treatment groups.

Mean otlertuzumab concentrations versus nominal time. Concentrations were similar between non-Hodgkin lymphoma (NHL) types.

(2015). Otlertuzumab (tru‐016), an anti‐cd37 monospecific adaptir™ therapeutic protein, for relapsed or refractory nhl patients. British Journal of Haematology, 168(1), 38-45.


Specifications

  • Immunogen
  • The details of the immunogen for this antibody are not available.
  • Host Species
  • Mouse
  • Derivation
  • Humanized (from mouse)
  • Type
  • VH - V-kappa - CH2 - CH3
  • Species Reactivity
  • Human
  • Applications
  • ELISA, IP, FC, FuncS, Neut, IF, ICC
  • CAS
  • 1372645-37-8
  • Generic Name
  • Otlertuzumab
  • MW
  • 107.5 kDa
  • Related Disease
  • Chronic lymphocytic leukemia (CLL)

Product Property

  • Purity
  • >95.0% as determined by analysis by SDS-PAGE.
  • Storage
  • Store at 4°C for up to 3 months. For longer term storage aliquot into small volumes and store at -20°C.

Applications

  • Application Notes
  • The CD37 antibody has been reported in applications of PK.

Target

  • Alternative Names
  • Otlertuzumab;1372645-37-8;TRU-016;CAS-024;SMIP-016;CD37;CD37 molecule;CD37 antigen;leukocyte antigen CD37;TSPAN26;tspan-26;tetraspanin-26;leukocyte surface antigen CD37;cell differentiation antigen 37;GP52-40;MGC120234

Related Resources

  • Biosimilar Overview
Please refer to Otlertuzumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Otlertuzumab.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "CD37"

Mouse Antibody

CAT Product Name Application Type
TAB-467CQ Anti-Human CD37 Recombinant Antibody (Lilotomab) ELISA, IHC, FC, IP, IF, FuncS IgG1, κ

ADCC Enhanced Antibody

CAT Product Name Application Type
AFC-TAB-467CQ Afuco™ Anti-CD37 ADCC Recombinant Antibody (Lilotomab), ADCC Enhanced ELISA, IHC, FC, IP, IF, FuncS ADCC enhanced antibody

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for TAB-904. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare